Compare SXC & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SXC | VOR |
|---|---|---|
| Founded | 1960 | 2015 |
| Country | United States | United States |
| Employees | 848 | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 555.4M | 755.7M |
| IPO Year | 2011 | 2021 |
| Metric | SXC | VOR |
|---|---|---|
| Price | $6.14 | $16.05 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 10 |
| Target Price | $9.00 | ★ $45.44 |
| AVG Volume (30 Days) | ★ 1.5M | 1.2M |
| Earning Date | 04-29-2026 | 05-13-2026 |
| Dividend Yield | ★ 7.58% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,600,300,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.30 | N/A |
| 52 Week Low | $5.52 | $0.13 |
| 52 Week High | $9.82 | $49.95 |
| Indicator | SXC | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 43.05 | 55.16 |
| Support Level | $5.52 | $11.38 |
| Resistance Level | $6.90 | $16.88 |
| Average True Range (ATR) | 0.21 | 1.63 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 3.08 | 50.81 |
SunCoke Energy Inc operates as an independent producer of coke in the Americas. Its coke is mainly used as a principal raw material in the blast furnace steelmaking process as well as in the foundry production of casted iron. The company operates through two segments: Domestic Coke and Industrial Services. It offers metallurgical and thermal coal. The company also provides handling and/or mixing services to steel, coke, electric utility, coal-producing, and other manufacturing-based customers. The majority of revenue is derived from the Domestic Coke segment.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.